Cohort characteristics
| Characteristics | IBD (n (%)) | Non-IBD* (n (%)) |
|---|---|---|
| Total number | 28833 | 4541987 |
| Male | 12748 (44) | 2222553 (49) |
| Mean age at entry (SD) | 38.3 (18.6) | 40.9 (19.5) |
| Cardiovascular disease-related drugs | ||
| Antihypertensive, antiarrhythmic and antihyperlipidaemic agents† | 12804 (44) | 1770474 (39) |
| Anticoagulant drugs‡ | 5072 (18) | 695541 (15) |
| Antidiabetic drugs§ | 1674 (6) | 222648 (5) |
| Socioeconomic status | ||
| Unknown, basic or no qualifications | 10528 (37) | 1618000 (36) |
| Medium-level qualifications | 2308 (8) | 369842 (8) |
| High-level qualifications | 1874 (6) | 342566 (8) |
| Self-employed, co-working spouse | 1233 (4) | 235758 (5) |
| Outside labour market | 8516 (30) | 1208873 (27) |
| Pensioned | 4340 (15) | 761680 (17) |
| Subtype of IBD | ||
| Crohn's disease (CD) | 7521 (26) | – |
| Ulcerative colitis (UC) | 19990 (69) | – |
| CD–UC/UC–CD¶ | 1322 (5) | – |
| Age at IBD diagnosis (years) | ||
| 15–34 | 10724 (37) | – |
| 35–49 | 6970 (24) | – |
| 50–64 | 5833 (20) | – |
| ≥65 | 5306 (18) | – |
| IBD drugs (ever use) | ||
| 5-Aminosalicylic acid | 18170 (63) | – |
| Azathioprine | 6192 (21) | – |
| Oral steroids | 15144 (53) | – |
| Tumour necrosis factor α antagonists | 1270 (4) | – |
| Major intestinal surgery | 4240 (15) | – |
*Non-IBD during follow up.
†ATC codes C0–C10; ‡ATC codes B01; §ATC codes A10.
¶Patients who changed diagnosis during follow up.
IBD, inflammatory bowel disease.